|
Market Closed -
Nasdaq
16:30:00 2026-10-21 EDT
|
5-day change | 1st Jan Change | ||
| 3.142 USD | -4.19% |
|
-8.11% | -69.36% |
| 08-11 | Intensity Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 | CI |
| 08-11 | Intensity Therapeutics, Inc., Q2 2026 Earnings Call, Aug 11, 2026 |
Company Valuation: Intensity Therapeutics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|
| Market Cap 1 | 117.5 | 26.58 | 24.64 | 10.26 | - | - |
| Change | - | -77.37% | -7.32% | -58.36% | - | - |
| Enterprise Value (EV) | 117.5 | 26.58 | 24.64 | 10.26 | 10.26 | 10.26 |
| Change | - | -77.37% | -7.32% | -58.36% | 0% | 0% |
| P/E | -6.21x | -1.5x | -1.2x | -0.93x | -1.48x | -1x |
| PBR | - | - | - | - | - | - |
| PEG | 0.2x | 0.1x | 0x | 0x | 0x | -0x |
| Capitalization / Revenue | - | - | - | - | - | 0.29x |
| EV / Revenue | - | - | - | - | - | 0.29x |
| EV / EBITDA | - | - | - | - | - | - |
| EV / EBIT | -0x | -0x | -0x | -0.85x | -0.69x | -0.39x |
| EV / FCF | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - |
| EPS 2 | -34.5 | -29.25 | -8.56 | -3.375 | -2.117 | -3.157 |
| Distribution rate | - | - | - | - | - | - |
| Net sales 1 | - | - | - | - | - | 34.96 |
| EBITDA | - | - | - | - | - | - |
| EBIT 1 | -8.319 | -16.58 | -11.97 | -12.08 | -14.88 | -26.33 |
| Net income 1 | -11.86 | -16.27 | -11.61 | -11.79 | -14.93 | -27.41 |
| Net Debt | - | - | - | - | - | - |
| Reference price 2 | 214.250 | 44.000 | 10.255 | 3.142 | 3.142 | 3.142 |
| Nbr of stocks (in thousands) | 548 | 604 | 2,403 | 3,265 | - | - |
| Announcement Date | 3/14/24 | 3/13/25 | 3/27/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.93x | - | - | - | 10.26M | |
| 19.17x | 6.81x | 13.53x | 1.55% | 66.22B | |
| 30.52x | 8.19x | 25.9x | 0.05% | 55.2B | |
| 36.31x | 6.45x | 19.27x | 0.89% | 52.79B | |
| 35.25x | 3.42x | 14.76x | -.--% | 45.53B | |
| 50.87x | 5.89x | 32.33x | -.--% | 43.94B | |
| -20.15x | 197.1x | -21.43x | -.--% | 41.64B | |
| 29.51x | 8.36x | 21.63x | 0.36% | 34B | |
| 29.85x | 6.32x | 16.4x | -.--% | 25.84B | |
| 32.16x | 5.92x | 19.93x | -.--% | 23.51B | |
| Average | 24.26x | 27.61x | 15.81x | 0.32% | 38.87B | |
| Weighted average by Cap. | 26.77x | 26.89x | 15.88x | 0.42% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- INTS Stock
- Valuation Intensity Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
